News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
773,844 Results
Type
Article (63468)
Company Profile (689)
Press Release (709687)
Section
Business (222429)
Career Advice (3154)
Deals (38172)
Drug Delivery (113)
Drug Development (87653)
Employer Resources (185)
FDA (17540)
Job Trends (16428)
News (377945)
Policy (37297)
Tag
Academia (2965)
Alliances (54805)
Alzheimer's disease (1337)
Approvals (17448)
Artificial intelligence (155)
Bankruptcy (383)
Best Places to Work (12426)
Biotechnology (474)
Breast cancer (130)
Cancer (1177)
Cardiovascular disease (109)
Career advice (2656)
Cell therapy (265)
Clinical research (69194)
Collaboration (420)
Compensation (201)
COVID-19 (2799)
C-suite (105)
Data (1156)
Diabetes (168)
Diagnostics (6643)
Earnings (90143)
Employer resources (162)
Events (120529)
Executive appointments (327)
FDA (18105)
Funding (378)
Gene therapy (200)
GLP-1 (685)
Government (4916)
Healthcare (20570)
Infectious disease (2892)
Inflammatory bowel disease (121)
Interviews (579)
IPO (17233)
Job creations (4427)
Job search strategy (2217)
Layoffs (476)
Legal (9237)
Lung cancer (190)
Manufacturing (199)
Medical device (14310)
Medtech (14315)
Mergers & acquisitions (21000)
Metabolic disorders (468)
Neuroscience (1642)
NextGen Class of 2024 (7491)
Non-profit (5046)
Northern California (1519)
Obesity (271)
Opinion (240)
Patents (112)
People (61538)
Pharmaceutical (137)
Phase I (21428)
Phase II (30266)
Phase III (22780)
Pipeline (470)
Postmarket research (2998)
Preclinical (9488)
Radiopharmaceuticals (257)
Rare diseases (244)
Real estate (6843)
Regulatory (24564)
Research institute (2629)
Resumes & cover letters (501)
Southern California (1341)
Startups (4036)
United States (14543)
Vaccines (648)
Weight loss (217)
Date
Today (5)
Last 7 days (703)
Last 30 days (3752)
Last 365 days (38172)
2024 (35066)
2023 (42398)
2022 (53746)
2021 (58500)
2020 (57436)
2019 (50980)
2018 (38763)
2017 (35760)
2016 (36017)
2015 (42009)
2014 (36186)
2013 (32036)
2012 (34333)
2011 (34577)
2010 (32901)
Location
Africa (1006)
Arizona (223)
Asia (44662)
Australia (7649)
California (3536)
Canada (1315)
China (265)
Colorado (158)
Connecticut (168)
Europe (100800)
Florida (472)
Georgia (127)
Illinois (398)
Indiana (215)
Kansas (103)
Maryland (625)
Massachusetts (2843)
Michigan (177)
Minnesota (294)
New Jersey (1002)
New York (1001)
North Carolina (839)
Northern California (1519)
Ohio (149)
Pennsylvania (870)
South America (1407)
Southern California (1341)
Texas (505)
Washington State (398)
773,844 Results for "pro dex inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Pro-Dex, Inc. Announces Fiscal 2024 Fourth Quarter and Full-Year Results
September 6, 2024
·
9 min read
Business
Pro-Dex, Inc. Announces Fiscal 2024 First Quarter Results
PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 first quarter ended September 30, 2023.
November 2, 2023
·
6 min read
Business
Pro-Dex, Inc. Announces Fiscal 2023 Third Quarter and Nine-Month Results
PRO-DEX, INC. announced financial results for its fiscal 2023 third quarter ended March 31, 2023.
May 4, 2023
·
8 min read
Business
Pro-Dex, Inc. Announces Fiscal 2023 Second Quarter and Six-Month Results
PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2023 second quarter ended December 31, 2022.
February 2, 2023
·
6 min read
Policy
Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform
Co-Diagnostics, Inc. announced that the Company has completed its first U.S. Food and Drug Administration application for 510 clearance for the Co-Dx™ PCR Pro™ instrument, and the Co-Dx PCR COVID-19 Test for over-the-counter use.
June 14, 2024
·
4 min read
Deals
Simulations Plus Acquires Pro-ficiency, Creating One-of-a-Kind Platform Spanning the Drug Development Continuum
Simulations Plus, Inc. announced the acquisition of Pro-ficiency Holdings, Inc. and its subsidiaries, a leader in providing simulation-enabled performance and intelligence solutions for clinical and commercial drug development.
June 12, 2024
·
8 min read
Policy
Venus Concept Announces Australian Regulatory Approval for Venus Versa Pro
Venus Concept Inc., a global medical aesthetic technology leader, announced that it has Therapeutic Goods Administration clearance in Australia to market the Venus Versa Pro system.
April 3, 2024
·
3 min read
Drug Development
Hi-Tech Pharmaceuticals Phase Two Launch of Revolutionary PRO IGF-1® -- The First Successful Production of Actual IGF-1 In A Dietary Supplement
Hi-Tech Pharmaceuticals moves into its Phase two launch of PRO IGF-1®.
June 26, 2024
·
3 min read
Policy
Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro
Co-Diagnostics, Inc. announced that it has submitted its Co-Dx™ PCR COVID-19 test with Co-Dx PCR Pro™ instrument for review by the U.S. Food and Drug Administration for Emergency Use Authorization.
December 27, 2023
·
4 min read
BioMidwest
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
Inhibikase Therapeutics, Inc. announced that the Company has received final meeting minutes from its recent pre-IND meeting with the Division of Cardiology and Nephrology of the U.S. Food and Drug Administration for IkT-001Pro as a candidate treatment for Pulmonary Arterial Hypertension.
May 9, 2024
·
5 min read
1 of 77,385
Next
